Oragenics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OGEN research report →
Companywww.oragenics.com
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
- CEO
- Janet Huffman
- IPO
- 2004
- Employees
- 3
- HQ
- Tampa, FL, US
Price Chart
Valuation
- Market Cap
- $2.64M
- P/E
- -0.26
- P/S
- 0.00
- P/B
- 0.41
- EV/EBITDA
- 0.54
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -177.32%
- ROIC
- -126.03%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-9,842,487 · 6.86%
- EPS
- $-4.56 · -185.00%
- Op Income
- $-9,362,503
- FCF YoY
- -107448.87%
Performance & Tape
- 52W High
- $9.60
- 52W Low
- $0.50
- 50D MA
- $0.65
- 200D MA
- $0.94
- Beta
- 1.26
- Avg Volume
- 250.88K
Get TickerSpark's AI analysis on OGEN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 12, 25 | Telling Fred | sell | 210 |
| Dec 11, 25 | Huffman Janet | other | 250,000 |
| Dec 11, 25 | Giordano Natasha | other | 125,000 |
| Dec 11, 25 | Giordano Natasha | other | 38,320 |
| Dec 11, 25 | Telling Fred | other | 125,000 |
| Dec 12, 25 | Telling Fred | sell | 210 |
| Dec 11, 25 | GANDOLFO JOHN P | other | 125,000 |
| Dec 11, 25 | DUNTON ALAN W | other | 125,000 |
| Dec 11, 25 | KOSKI ROBERT C | other | 125,000 |
| Dec 11, 25 | POPE CHARLES L | other | 125,000 |
Our OGEN Coverage
We haven't published any research on OGEN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OGEN Report →